Neuphoria Therapeutics Inc.

NEUP ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Assets
Cash & Equivalents $19.9M $19.4M $22.2M $13.6M $14.2M $17.0M $4.3M $8.1M
Accounts Receivable $813.4K $1.6M $1.1M $1.8K $11.9K $24.6K $35.6K $116.0K
Inventory — — — — — — — —
Total Current Assets $21.1M $21.7M $23.4M $14.0M $15.0M $17.1M $4.4M $8.4M
Property, Plant & Equipment — — — $2.6K $2.8K $1.6K $1.7K $2.0K
Goodwill $3.5M $8.8M $8.7M $8.7M $8.6M $8.5M $8.4M $8.9M
Intangible Assets (Excl. Goodwill) $4.1M $4.3M $4.5M $4.6M $4.8M $5.0M $5.1M $5.3M
Total Assets $28.7M $34.8M $36.6M $27.3M $28.6M $30.7M $18.2M $22.9M
Liabilities
Accounts Payable $385.6K $627.2K $520.7K $1.4M $1.2M $745.3K $1.5M $1.3M
Total Current Liabilities $756.6K $1.5M $2.6M $5.1M $4.2M $1.6M $2.1M $2.6M
Long-Term Debt — — — — — — — —
Total Liabilities $4.1M $5.4M $6.9M $14.8M $9.6M $4.7M $4.4M $5.8M
Stockholders' Equity
Retained Earnings $-191.8M $-186.9M $-186.4M $-188.3M $-178.3M $-169.5M $-180.7M $-178.8M
Total Stockholders' Equity $24.6M $29.4M $29.7M $12.5M $19.0M $26.0M $13.7M $17.1M
← Newer Page 1 of 2 Older →